Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003)

Blood

Volumn 98, Issue 1, 2001, Pages 41-48

  Dhodapkar, Madhav V ^{a,b,c,d,e,f,g,h,i}   Jacobson, Joth L ^{a,b,c,d,e,f,g,h,i}   Gertz, Morie A ^{a,b,c,d,e,f,g,h,i}   Rivkin, Saul E ^{a,b,c,d,e,f,g,h,i}   David Roodman, G ^{a,b,c,d,e,f,g,h,i}   Tuscano, Joseph M ^{a,b,c,d,e,f,g,h,i}   Shurafa, Muhammad ^{a,b,c,d,e,f,g,h,i}   Kyle, Robert A ^{a,b,c,d,e,f,g,h,i}   Crowley, John J ^{a,b,c,d,e,f,g,h,i}   Barlogie, Bart ^{a,b,c,d,e,f,g,h,i}  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Statistical Center   (United States)

^c MAYO CLINIC   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁱ Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN M; PURINE NUCLEOSIDE DERIVATIVE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG ACTIVITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; SYMPTOM; UNITED STATES; WALDENSTROEM MACROGLOBULINEMIA;

EID: 18144449054     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.1.41     Document Type: Article

References (33)

1. Waldenström JG. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia: a new syndrome? Acta Med Scand. 1944;117:216-222.
2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
3. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214-225.
4. MacKenzie MR, Fudenberg HH. Macroglobulinemia: an analysis for forty patients. Blood. 1972; 39:874-889.
5. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc. 1987;62:719-731.
6. McAllister BD, Bayrd ED, Harrison EG, McGuckin WF. Primary macroglobulinemia: review with a report on 31 cases and notes on the value of continuous chlorambucil therapy. Am J Med. 1967;43:394-434.
7. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737-742.
8. Cheson BD. New prospects in the treatment of indolent lymphomas with purine analogues. Cancer J Sci Am. 1998;4(suppl 2):S27-S36.
9. Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. 2-Chlorodeoxyadenosine therapy in Waldenström's macroglobulinaemia. Nouv Rev Fr Hematol. 1994;36:317-320.
10. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2-Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol. 1994;5:288-289.
11. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol. 1998;16:2060-2064.
12. Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol. 1998;103:690-695.
13. Zinzani PL, Gherlinzoni F, Bendandi M, et al. Fludarabine treatment in resistant Waldenström's macroglobulinemia. Eur J Haematol. 1995;54:120-123.
14. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med. 1993;95:49-52.
15. Foran JM, Rohatiner AZ, Coiffler B, et al. Multi-center phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle cell lymphoma. J Clin Oncol. 1999;17:546-553.
16. Dimopoulos MA, Alexanian R. Waldenström's macroglobulinemia. Blood. 1994;83:1452-1459.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
19. Cox DR. Regression models and life tables. Stat Soc. 1972;34:187-202.
20. Cox DR. The Analysis of Binary Data. London, England: Methuen; 1970.
21. Crowley J, LeBlanc M, Gentleman R, Salmon S. Exploratory Methods in Survival Analysis: Analysis of Censored Data. Hayward, CA: Institute of Mathematical Sciences; 1995;27:55-77. IMS Lecture Notes Monograph Series.
22. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998;25:42-59.
23. Case D, Ervin T, Boyd M, Redfield D. Waldenström's macroglobulinemia: long term results with the M-2 protocol. Cancer Invest. 1991;9:1-7.
24. Desikan R, Dhodapkar M, Siegel D, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br J Haematol. 1999;105:993-996.
25. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
26. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525-1527.
27. Bartl R, Frisch B, Mahl G, et al. Bone marrow histology in Waldenström's macroglobulinemia: clinical relevance of histologic subtypes. Scand J Hematol. 1983;31:359-375.
28. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol. 1993;11:1553-1558.
29. Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939-2045.
30. Carter P, Koval J, Hobbs J. The relation of clinical and laboratory findings to the survival of patients with macroglobulinemia. Clin Exp Immunol. 1977;28:241-249.
31. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström's macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852-858.
32. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387.
33. Mori M, Terui Y, Ikeda M, et al. β-Microglobulin identified as an apoptosis-inducing factor and its characterization. Blood. 1999;94:2744-2753.